/NLSP
NLSP Stock - NLS Pharmaceutics AG
Healthcare|BiotechnologyNASDAQ
$2.91-12.61%
$0.42 (-12.61%) • Dec 12
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.9
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.20
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NLSP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.88 – $2.94
TARGET (TP)$3.35
STOP LOSS$2.68
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.13
52W High$43.40
52W Low$0.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-3,321 | $-11,408 | $-11,408 | $-10,050 | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-4,380,113 | $-11,807,063 | $-15,482,360 | $-11,860,620 | $-2,299,370 |
| Net Income | $-1,980,810 | $-12,172,029 | $-16,495,680 | $-11,946,078 | $-2,861,435 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-26.30 | $-3.20 | $-8.40 | $-8.10 | $-5.90 |
Company Overview
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NLSPBeat Rate
100%
Last 5 quarters
Avg Surprise
+97.2%
EPS vs Estimate
Beats / Misses
5/0
Last 12 quarters
Latest EPS
$-5.54
Q4 2025
EPS Surprise History
Q2 21
+95.0%
$-0.34vs$-6.80
Q3 21
No data
Q1 22
+96.4%
$-0.50vs$-13.80
Q4 22
No data
Q2 23
+97.5%
$-0.29vs$-12.00
Q2 23
+97.1%
$-0.20vs$-6.80
Q2 24
+100.0%
$-0.00vs$-8.40
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 6, 2025 | — | $-5.54 | — | — |
Q2 2025 | May 16, 2025 | — | — | — | — |
Q4 2024 | Oct 18, 2024 | — | — | — | — |
Q2 2024 | May 15, 2024 | $-8.40 | $-0.00 | +100.0% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-6.80 | $-0.20 | +97.1% | ✓ BEAT |
Q2 2023 | May 5, 2023 | $-12.00 | $-0.29 | +97.5% | ✓ BEAT |
Q4 2022 | Oct 11, 2022 | — | $-0.54 | — | — |
Q1 2022 | Mar 24, 2022 | $-13.80 | $-0.50 | +96.4% | ✓ BEAT |
Q3 2021 | Sep 28, 2021 | — | $-0.42 | — | — |
Q2 2021 | May 14, 2021 | $-6.80 | $-0.34 | +95.0% | ✓ BEAT |
Q2 2020 | Jun 30, 2020 | — | $-0.11 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.18 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.31 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-19.32 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-13.57 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.16 | — | — |
Latest News
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 30, 2025, 11:50 PM
NLS Pharma And Aexon Labs Expand DOXA Platform With AEX-6xx Series, New Generation Of Small Molecules Targeting Arousal Stability, Cognition, And Neuroprotection
📈 PositiveBenzinga•Oct 30, 2025, 11:15 AM
NLS Pharmaceutics shares are trading lower after the company announced its plans to effect a reverse share split at 1-for-10, effective October 31.
📉 NegativeBenzinga•Oct 29, 2025, 05:11 PM
NLS Pharmaceutics Plans To Effect A Reverse Share Split At 1-for-10, Effective October 31, Under The New Trading Symbol "NCEl", And New Name, NewcelX, Following The Anticipated Closing Of The Merger With Kadimastem
➖ NeutralBenzinga•Oct 29, 2025, 10:11 AM
NLSP stock has given up its prior gain. NLS Pharmaceutics shares were trading higher after the company signed an MOU with Kadimastem to jointly develop gene-edited cell therapy products.
➖ NeutralBenzinga•Oct 27, 2025, 12:28 PM
NLS Pharmaceutics shares are trading higher after the company signed an MOU with Kadimastem to jointly develop gene-edited cell therapy products.
📈 PositiveBenzinga•Oct 27, 2025, 11:04 AM
NLS Pharmaceutics And Kadimastem Sign MOU To Jointly Develop Gene-Edited Cell Therapy Products
📈 PositiveBenzinga•Oct 27, 2025, 11:04 AM
NLS Pharmaceutics, Kadimastem Receive Approval To List Common Shares On Nasdaq After Merger Under NewcelX Name, NCEL Ticker
📈 PositiveBenzinga•Oct 23, 2025, 10:04 AM
NLS Pharmaceutics H1 EPS $(1.05) Up From $(1.94) YoY
📈 PositiveBenzinga•Oct 6, 2025, 10:49 AM
NLS Pharmaceutics Shareholders Approve Merger With Kadimastem
📈 PositiveBenzinga•Sep 30, 2025, 11:06 AM
NLS Pharmaceutics And Kadimastem Announce SEC Effectiveness Of Registration Statement On Form F-4 For Planned Merger Into NewCelX Ltd
➖ NeutralBenzinga•Sep 10, 2025, 10:12 AM
NLS Pharmaceutics And Merger Partner Kadimastem Announce A Hong Kong Patent Covering Kadimastem's Cell-Selection And Enrichment Technology For IsletRx
📈 PositiveBenzinga•Sep 4, 2025, 11:43 AM
NLS Pharmaceutics shares are trading lower after the company announced it rescheduled its shareholder meeting to address SEC feedback and provide updated information.
📉 NegativeBenzinga•Aug 26, 2025, 04:54 PM
Reported Monday August 25, 2025: NLS Pharmaceutics Postpones Shareholders' Meeting On Kadimastem Merger To September 16 To Address SEC Feedback And Provide Updated Information
➖ NeutralBenzinga•Aug 26, 2025, 04:52 PM
Frequently Asked Questions about NLSP
What is NLSP's current stock price?
NLS Pharmaceutics AG (NLSP) is currently trading at $2.91 per share. The stock has moved -12.61% today.
What is the analyst price target for NLSP?
No analyst price targets are currently available for this stock.
What sector is NLS Pharmaceutics AG in?
NLS Pharmaceutics AG operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NLSP's market cap?
NLS Pharmaceutics AG has a market capitalization of $0.00 billion, making it a small-cap company.
Does NLSP pay dividends?
No, NLS Pharmaceutics AG does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBACK
IMAC Holdings, Inc.
$0.13
Mkt Cap: $0.0B
BCTXW
BriaCell Therapeutics Corp.
$0.04
Mkt Cap: $0.0B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
CERO
CERo Therapeutics Holdings, Inc.
$0.10
Mkt Cap: $0.0B
KTTA
Pasithea Therapeutics Corp.
$1.16
Mkt Cap: $0.0B
NUWE
Nuwellis, Inc.
$2.16
Mkt Cap: $0.0B
OCEA
Ocean Biomedical, Inc.
$0.00
Mkt Cap: $0.0B
PRE
Prenetics Global Limited
$17.48
Mkt Cap: $0.2B
SABS
SAB Biotherapeutics, Inc.
$3.99
Mkt Cap: $0.0B
SRZN
Surrozen, Inc.
$21.76
Mkt Cap: $0.2B
Explore stocks similar to NLSP for comparison